Programmed cell death ligand 1 expression in a case of poorly differentiated lymphocyte-rich hepatocellular carcinoma.

Ginji OmoriTakahiro OsugaKoji MiyanishiKota HamaguchiShingo TanakaHiroyuki OhnumaKazuyuki MuraseKohichi TakadaMinoru NagayamaYasutoshi KimuraIchiro TakemasaYasuhiro KikuchiToshihiko TorigoeJunji Kato

Published in: Clinical case reports (2021)

Our pathological study of a case of poorly differentiated lymphocyte-rich hepatocellular carcinoma suggested that immune checkpoint inhibitor may be an effective therapy. The histological type is an important factor in determining treatment choices.

Keyphrases

peripheral blood
poor prognosis
stem cells
binding protein
mesenchymal stem cells
combination therapy